Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study introduced and evaluated Ahmad's NPRT system for documenting hair loss, finding it helpful in assessing the specific state of male pattern baldness in 500 patients.

This study found that male hospital staff in China had a higher prevalence of androgenetic alopecia compared to the general male population, while there was no significant difference among females.

This study found that daily use of 1% pyrithione zinc shampoo modestly improved hair growth over 26 weeks, although these effects were less than those of 5% minoxidil.

This study suggests that Botox injections may increase hair count and reduce hair loss in men with androgenetic alopecia, potentially through increased blood flow and oxygen to the scalp.

Botulinum toxin injections can reduce hair loss and stimulate new hair growth in some men with male pattern baldness.

Botulinum toxin-A injections in the scalp can reduce hair loss and promote new hair growth in men with certain types of baldness.

A man's skin cancer improved and some of his hair grew back after treatment with a special light therapy and a medication.

This study found that 58% of men aged 30-50 had androgenic alopecia, with disease severity increasing with age and many being candidates for medical treatment or hair transplantation.

This study reported that a novel cell culture medium gel significantly increased hair counts and reduced hair loss in men with androgenetic alopecia over a six-month period.

This article reports on a partial regrowth of scalp hair in a patient treated with extracorporeal photochemotherapy and interferon α 2a, but provides no new clinical outcomes.

This review discusses scalp reduction surgery for male-pattern baldness, highlighting its effectiveness in reducing bald areas when hair transplantation alone is not sufficient, without increasing total hair volume.

This study suggests that any baldness, particularly moderate balding, is associated with a higher risk of fatal prostate cancer in men, supporting a possible link between hair loss and prostate cancer mechanisms.

This study found that sebaceous glands in bald scalp have greater androgen binding affinity and capacity than those in hairy scalp, possibly contributing to the androgenic response seen in male pattern baldness.

This study found that platelet-rich plasma combined with topical minoxidil was more effective in increasing hair density for male-type baldness than either treatment alone.

This study found no significant association between the degree of male-pattern baldness and serum 25-hydroxyvitamin D levels in healthy middle-aged and older men.

This clinical trial found that combining 678 nm helmet-type low-level laser therapy with topical minoxidil 5% significantly increased hair density and patient satisfaction in men with androgenetic alopecia, compared to using minoxidil alone. Both treatments were well tolerated.

In this study, researchers found that the existing Norwood and Hamilton classifications for androgenetic alopecia in Indian males had significant limitations, with 18% of cases not fitting into existing pattern categories.

This research suggests that intraoperative unilateral occipital artery ligation can reduce the risk of complications like scalp necrosis, offering advantages such as improved visualization and reduced asymmetry during extensive scalp lift surgeries.

This study found that the prevalence of androgenetic alopecia in Chinese men was lower than in Caucasian men, similar to Korean men, and most commonly presented as type III vertex.

This study suggests the average age of onset for androgenic alopecia may be decreasing, but a longer-term study is needed to confirm this observation.

In this study, the vertex type of male pattern baldness was associated with increased cardiovascular risk factors, suggesting it may serve as a marker for cardiovascular evaluation in men.

This study explored how modifying the 8-substituent of 8-bromobenzoquinolinone affects its selectivity in inhibiting both 5 alpha-reductase isozymes in the scalp.

This study found that the prevalence of androgenetic alopecia in Chinese men and women was lower than in Caucasians and similar to that in Koreans.

This review discusses botulinum toxin's experimental off-label uses in dermatology, highlighting promising results but emphasizing the need for more clinical trials to confirm efficacy and safety.

This study examined young Ukrainian men with alopecia areata and found that different severities of the condition were associated with distinct clinical and trichoscopic features, such as variations in hair loss, stress levels, and nail involvement, among others.

This study found that the SRD5A2 A49T A variant is associated with an increased risk of prostate cancer, lower circulating 3α‐diolG levels, and a decreased risk of baldness.

This study found that using a specific ratio method based on the patient's scalp measurements can effectively predict the dimensions of the permanent safe zone for hair transplants, particularly in early stages of androgenetic alopecia, potentially ensuring long-lasting transplant results.

This review discusses the role of androgen metabolism in hair follicles and its potential impact on future treatments for androgenetic alopecia, but reports no clinical results.

This study found that trichoscopic parameters in male androgenetic alopecia deteriorated progressively with increasing disease severity and were significantly linked to genetic, metabolic, and psychosocial factors.

This study reported that 19.8% of patients experienced telogen hair loss after COVID-19, with most cases occurring 3 to 6 months post-recovery, and noted a rapid progression in patients with androgenetic alopecia, as well as cases of alopecia areata and cicatricial alopecia linked to COVID-19.